Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Neoplasia ; 23(4): 391-399, 2021 04.
Article in English | MEDLINE | ID: mdl-33784591

ABSTRACT

Notwithstanding that high rates of glucose uptake and glycolysis are common in neoplasia, pharmacological efforts to inhibit glucose utilization for cancer treatment have not been successful. Recent evidence suggests that in addition to classical glucose transporters, sodium-glucose transporters (SGLTs) are expressed by cancers. We therefore investigated the possibility that SGLT inhibitors, which are used in treatment of type 2 diabetes, may exert antineoplastic activity by limiting glucose uptake. We show that the SGLT2 inhibitor canagliflozin inhibits proliferation of breast cancer cells. Surprisingly, the antiproliferative effects of canagliflozin are not affected by glucose availability nor by the level of expression of SGLT2. Canagliflozin reduces oxygen consumption and glutamine metabolism through the citric acid cycle. The antiproliferative effects of canagliflozin are linked to inhibition of glutamine metabolism that fuels respiration, which represents a previously unanticipated mechanism of its potential antineoplastic action.


Subject(s)
Antineoplastic Agents/pharmacology , Breast Neoplasms/drug therapy , Canagliflozin/pharmacology , Citric Acid Cycle/drug effects , Oxygen Consumption/drug effects , Sodium-Glucose Transporter 2 Inhibitors/pharmacology , Animals , Cell Line, Tumor , Cell Proliferation/drug effects , Cell Respiration/drug effects , Diabetes Mellitus, Type 2/drug therapy , Female , Glucose/metabolism , Glutamate Dehydrogenase/genetics , Glutamic Acid/metabolism , Humans , MCF-7 Cells , Mice , Mitochondria/metabolism , RNA Interference , RNA, Small Interfering/genetics , Sodium-Glucose Transporter 2/drug effects , Sodium-Glucose Transporter 2/genetics , Sodium-Glucose Transporter 2/metabolism
2.
Proc Natl Acad Sci U S A ; 117(14): 7613-7621, 2020 04 07.
Article in English | MEDLINE | ID: mdl-32209666

ABSTRACT

Inspired largely by the role of the posttranslationally modified amino acid dopa (DOPA) in mussel adhesion, catechol functional groups have become commonplace in medical adhesives, tissue scaffolds, and advanced smart polymers. Yet, the complex redox chemistry of catechol groups complicates cross-link regulation, hampering fabrication and the long-term stability/performance of mussel-inspired polymers. Here, we investigated the various fates of DOPA residues in proteins comprising mussel byssus fibers before, during, and after protein secretion. Utilizing a combination of histological staining and confocal Raman spectroscopy on native tissues, as well as peptide-based cross-linking studies, we have identified at least two distinct DOPA-based cross-linking pathways during byssus fabrication, achieved by oxidative covalent cross-linking or formation of metal coordination interactions under reducing conditions, respectively. We suggest that these end states are spatiotemporally regulated by the microenvironments in which the proteins are stored prior to secretion, which are retained after formation-in particular, due to the presence of reducing moieties. These findings provide physicochemical pathways toward greater control over properties of synthetic catechol-based polymers and adhesives.


Subject(s)
Bivalvia/metabolism , Catechols/metabolism , Dihydroxyphenylalanine/metabolism , Amino Acid Sequence , Animals , Catechols/chemistry , Oxidation-Reduction , Peptides/chemistry , Peptides/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...